Deep Track Capital

Plus: Updates from Glycomine, Attovia, Thirtyfivebio, Heparegenix, Duality, Pelthos and Third Harmonic

Vertex competitor posts a first-day gain after an upsized offering; plus financings for Gh Research and Tectonic

Also in BioCentury’s weekly Venture Report: Formela stepping back from Atlas’ new fund, nine-digit rounds for Nuvig and Maze, and more

Public Equity Report: French biotech to fund MASH study with €348M lifeline; bispecifics developer raises $250; DMD cardiomyopathy play prices follow-on

BioCentury’s latest Venture Report also features news about LoQus23, Aktis, Resolution, Triveni, Flagship and more

Indiana-based developer of long-acting peptide therapeutics is latest mid-to-late-stage biotech to seek NASDAQ listing

Plus: Abata draws strategic investment from BMS as it preps first human study in multiple sclerosis

Plus: Financings for newcos Nilo, Jade, Red Queen

German biotech raised series B2 round in March to push two highly stable ADC candidates into the clinic, and discover new payloads

Plus: IPO updates from Sunho, Rapport; Bicycle’s massive PIPE; Dyne’s opportunistic follow-on; and more